What You Should Know:
– Today, Accenture announced it has acquired Bionest, a strategy and consulting firm dedicated to addressing complex strategic decisions for leading biopharma organizations across innovative areas of science including precision medicine and diagnostics, oncology, cell & gene therapy (CGT), and rare diseases. Terms of the transaction were not disclosed.
– Scientific and technological advancements are creating breakthroughs for patient health, resulting in more complex and personalized therapies.
– Bionest’s team of 46 scientifically-minded consultants, industry executives, and specialists will join Accenture Strategy in the Life Sciences practice, broadening and deepening the firm’s capabilities in life science’s most exciting and challenging areas.
